The National Institute for Health and Clinical Excellence (NICE) has announced their initial draft guidance on the use of Exubera® (inhaled insulin).
They have stated that it should not be recommended for the treatment of anyone with diabetes, except for those taking part in clinical studies.
Exubera® was granted a licence by the European Medicines Evaluation Agency (EMEA) in January.
“Diabetes UK believes that access to new developments should not be restricted on the basis of cost and should take into account patient choice and preference," said Simon O'Neill, Director of Care at Diabetes UK.
"We would like to urge NICE to reconsider its recommendations to take more account of the patients' perspective and meet individual needs and preferences."
“This is a medical breakthrough and it is the potential first step to improving the lives of some people with diabetes. It will be unfortunate if people in England have limited access whilst it becomes available in other countries.”
However, there is an urgent need for more research to support the improvements made by using inhaled insulin on quality of life. A quick review of all the research, when available, must be undertaken to avoid any further delays in access.